B+
Bull case
20%
Probability
Target price
$460.00
+56.8% vs current
Tone is cautiously constructive after the Q3 release: durable procedure demand and product momentum support sentiment, while margin sensitivity to input costs and regulatory clarity keep positioning conservative.
No evidence quality warning is currently attached to this memo.
New approvals and commercial rollouts (spine, robotics) expand addressable market and enable premium pricing and mix improvement.
Reimbursement cuts, device recalls, or component shortages could compress near-term revenue and margins materially.
Sustained hospital procedure volumes and backlog reduction drive implant and trauma sales, supporting multi-quarter organic growth.
No formal recommendation provided.